SynuSight Biotech has licensed 18 F-FD4 to XingImaging and to ABLi Therapeutics to evaluate alpha-synuclein clearance from the brain in response to risvodetinib treatment . SHANGH ...

A groundbreaking study reveals that ultrasensitive ctDNA assays significantly enhance prognosis for large B-cell lymphoma, outperforming traditional PET assessments.

A proof-of-concept trial shows novel sarcoidosis PET/CT tracer detects inflammatory activity, supporting further clinical ...

PET scans may serve as both a diagnostic and prognostic tool in giant cell arteritis (GCA), according to a new study. In over 100 patients with GCA who underwent 18 F-fluorodeoxyglucose (FDG) PET ...

The study published in JAVMA highlights a critical lack of veterinary-specific data on PET/CT radiation exposure.

April 25, 2012 (New Orleans, Louisiana) — Misdiagnosis of Alzheimer's disease (AD) based on positron emission tomography (PET) scan readings appears to be a troubling problem that could get worse as ...

Molecular imaging specialist Jan Grimm says Cerenkov imaging could provide a cheaper, faster imaging approach for areas where access to PET scans is limited. Positron emission tomography (PET) is one ...

Positron Emission Tomography (PET) is a nuclear medicine procedure used to examine various body tissue functions to identify certain conditions. Biochemical changes in an organ or tissue can be traced ...

Medicare may cover positron emission tomography (PET) scans. If you have a PET scan as an inpatient, Part A will typically cover costs. If you are an outpatient, Part B will cover eligible expenses.

SynuSight Biotech ("SynuSight"), a biotechnology company dedicated to the development of diagnostic solutions for neurodegenerative diseases and ABLi Therapeutics ("ABLi"), a biotechnology company ...